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Most patients with autoimmune polyendocrine syndrome type I (APS-I) display chronic mucocu-
taneous candidiasis (CMC). We hypothesized that this CMC might result from autoimmunity to 
interleukin (IL)-17 cytokines. We found high titers of autoantibodies (auto-Abs) against IL-17A, 
IL-17F, and/or IL-22 in the sera of all 33 patients tested, as detected by multiplex particle-based 
flow cytometry. The auto-Abs against IL-17A, IL-17F, and IL-22 were specific in the five patients 
tested, as shown by Western blotting. The auto-Abs against IL-17A were neutralizing in the only 
patient tested, as shown by bioassays of IL-17A activity. None of the 37 healthy controls and 
none of the 103 patients with other autoimmune disorders tested had such auto-Abs. None of 
the patients with APS-I had auto-Abs against cytokines previously shown to cause other well-
defined clinical syndromes in other patients (IL-6, interferon [IFN]-, or granulocyte/macrophage 
colony-stimulating factor) or against other cytokines (IL-1, IL-10, IL-12, IL-18, IL-21, IL-23, 
IL-26, IFN-, tumor necrosis factor [], or transforming growth factor ). These findings suggest 
that auto-Abs against IL-17A, IL-17F, and IL-22 may cause CMC in patients with APS-I.
© 2010 Puel et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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IL-22–producing human T cells (Acosta-Rodriguez et al., 
2007; Liu et al., 2009). Furthermore, patients with STAT3 de-
ficiency display a predisposition to CMC (and staphylococcal 
disease) and lack IL-17–producing T cells (de Beaucoudrey 
et al., 2008; Ma et al., 2008; Milner et al., 2008; Minegishi 
et al., 2009). Similarly, some patients with IL-12p40 or 
IL-12R1 deficiency present CMC (together with myco-
bacteriosis and salmonellosis) and have lower than normal 
proportions of IL-17–producing T cells (de Beaucoudrey 
et al., 2008). Finally, patients with rare defects of CARD9, 
which normally controls the production of IL-17 in response 
to dectin-1 and -2 stimulation by Candida, suffer from candi-
diasis (LeibundGut-Landmann et al., 2007; Glocker et al., 
2009; Robinson et al., 2009). We therefore hypothesized 
that autoimmunity to IL-17 cytokines might account for 
CMC in patients with APS-I.
RESULTS AND DISCUSSION
We searched for auto-Abs against IL-17 cytokines (IL-17A, 
IL-17F, IL-22, and IL-26, which is absent from mice) or 
against IL-17–inducing cytokines (IL-1, IL-6, IL-21, IL-
23, and TGF-) in 33 patients diagnosed with APS-I on 
the basis of autoimmune polyendocrinopathy, circulating 
auto-Abs against IFN- and –, and the presence of two 
mutant AIRE alleles (Table I). CMC was observed in 29 
out of the 33 patients (Table I). Multiplex particle-based 
flow cytometry revealed a high fluorescence intensity (FI; 
>1,000, arbitrary definition) of IgG auto-Abs against IL-
17A in the plasma of 22 patients, with a high FI of auto-Abs 
against IL-17F in 31 patients and of auto-Abs against IL-22 
in 30 patients (Fig. 1 and Table I). All 33 patients had sig-
nificant (P = 6.4 × 109, 4.6 × 1012, and 2.16 × 1011, re-
spectively) levels of auto-Abs against at least one of these 
three cytokines. 5 patients had a significant reaction against 
a single cytokine, 6 had a reaction against two cytokines, 
and 22 had a reaction against all three cytokines. No auto-
Abs against IL-17A, IL-17F, and IL-22 were found in 
plasma samples from the 37 healthy individuals tested. Sim-
ilarly, no auto-Abs against any of these three cytokines 
were found in plasma samples from another 103 patients 
with various autoimmune conditions (Fig. S4, A and B). 
No auto-Abs against IL-1, IL-6, IL-23, or IL-26 (whether 
as a monomer or a dimer) were found in the APS-I patients 
(Fig. S3, A–D). There were no auto-Abs against IL-12, 
IFN-, or GM-CSF (Fig. S3, E–G), consistent with the 
lack of mycobacterial disease and alveolar proteinosis in pa-
tients with APS-I. No auto-Abs were found against any of 
the other cytokines tested, including IL-10, IL-18, IFN-, 
and TNF (Fig. S3, H–K). As expected, all APS-I patients 
had auto-Abs against IFN- (Fig. 1 and Table I) and IFN- 
(not depicted). In addition, no IgA antibodies, a key ele-
ment of mucosal immunity, directed against IL-17A, IL-17F, 
or IL-22 were detected in the plasma of 21 APS-I patients 
by classical ELISA (not depicted).
We also ran classical ELISA, with plasma samples diluted 
by a factor of five more than in the multiplex assays. 4 out of 
Autoimmune polyendocrine syndrome type I (APS-I), also 
known as autoimmune polyendocrinopathy with candidiasis 
and ectodermal dystrophy (Online Mendelian Inheritance in 
Man no. 240300), is a rare, autosomal recessive primary im-
munodeficiency first described clinically in 1929 (Notarangelo 
et al., 2006; Husebye et al., 2009). APS-I is characterized 
principally by multiple autoimmune endocrinopathies, hypo-
parathyroidism, and adrenal insufficiency in particular, with 
some of these symptoms being caused by pathogenic auto-
antibodies (auto-Abs). A genome-wide mapping approach led 
to the identification of APS-I–causing mutations in the AIRE 
gene in 1997 (Finnish-German APECED Consortium, 1997; 
Nagamine et al., 1997). Autoimmunity in patients with APS-I 
may be accounted for by the key role of AIRE in tolerance. 
AIRE is expressed in the thymus, where it contributes to the 
expression of peripheral antigens (Anderson et al., 2002; 
Mathis and Benoist, 2009). This gene has also been shown to 
be expressed in secondary lymphoid organs, where it also 
contributes to tolerance (Gardner et al., 2008). Surprisingly, 
most patients with APS-I suffer from chronic mucocutaneous 
candidiasis (CMC) without displaying any marked suscepti-
bility to any other pathogen. The product of the AIRE gene 
is not involved in any known cellular pathway governing host 
defense. The pathogenesis of CMC in patients with APS-I has 
thus remained both intriguing and elusive.
High titers of auto-Abs against some type I IFNs, includ-
ing IFN- and - in particular, are found in all patients 
(Meager et al., 2006; Meloni et al., 2008). These auto-Abs 
are a hallmark of APS-I and are therefore useful for diagnos-
tic purposes (Husebye et al., 2009). However, they confer 
no particular overt predisposition to viral diseases, perhaps 
because of the large number of redundant type I IFN species, 
resulting in incomplete neutralization of the overall antiviral 
activity of IFNs by the auto-Abs. It has been suggested that 
these auto-Abs contribute to CMC in APS-I patients (Meager 
et al., 2006). However, this is now thought unlikely be-
cause of the absence of CMC in patients with various forms 
of STAT1 and TYK2 deficiency and impaired responses to 
type I IFNs, and in patients with various forms of NEMO, 
UNC-93B, and TLR3 deficiencies and impaired production 
of type I IFNs (Minegishi et al., 2006; Zhang et al., 2008; 
Chapgier et al., 2009). Nevertheless, based on this observa-
tion, we hypothesized that CMC in patients with APS-I 
might result from autoimmunity to cytokines other than 
type I IFNs potentially involved in protective immunity to 
Candida albicans in the skin and mucosae.
Recent studies in the mouse have suggested that IL-17 
cytokines, such as IL-17A, IL-17F, and IL-22 (Korn et al., 
2009), may be important in host defense against Candida 
(Conti et al., 2009; van de Veerdonk et al., 2009). However, 
it is difficult to assess mucocutaneous immunity to Candida in 
mice (Netea et al., 2008), in which IL-17 cytokines seem to 
be important for the control of various other pathogens, par-
ticularly in the lungs and gastrointestinal tract (Dubin and 
Kolls, 2008; Khader et al., 2009). Stimulation with Candida 
in vitro leads to the preferential generation of IL-17A– and 
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IFN-, IFN-, IL-17A, IL-17F, and IL-22 (Fig. 1, Fig. S1, 
and Table I). Moreover, all 33 patients with APS-I had 
auto-Abs against at least one out of three IL-17 cytokines 
(IL-17A, IL-17F, and IL-22). High titers of auto-Abs against 
all three of these cytokines were found in 22 patients.
We performed Western blotting to assess the specificity 
of these auto-Abs. Plasma samples from five patients with 
APS-I and auto-Abs against IL-17A, IL-17F, and/or IL-22, 
as detected by ELISA and multiplex particle-based flow cy-
tometry, and from a healthy individual were tested for their 
ability to recognize rIL-17A, rIL-17F, and rIL-22 on West-
ern blots. The three cytokines were clearly recognized by 
plasma samples from patients but not by the control plasma 
(Fig. 2). The plasma samples from patients did not recognize 
IL-23 in a control assay. Finally, we investigated whether the 
auto-Abs against IL-17A neutralized this cytokine in a simple 
the 30 patients tested had high titers of IgG (OD > 1) auto-
Abs against IL-17A (P = 0.056), 10 patients had high titers 
of auto-Abs against IL-17F (P = 1.4 × 107), and 12 patients 
had high titers of auto-Abs against IL-22 (P = 1.23 × 107; 
Fig. S1 and Table I). 17 patients had auto-Abs against at least 
one of these three cytokines, including 10 patients with 
auto-Abs against a single cytokine, 5 patients with auto-Abs 
against two cytokines, and 2 patients with auto-Abs against 
all three cytokines. No such auto-Abs were detected in the 
37 healthy controls tested. This assay was not used to test 
patients with various autoimmune diseases. There were no 
detectable auto-Abs against TGF-1, IL-6, IL-21, IL-23, or 
IL-26, or against IL-12 or IFN- in any of the APS-I pa-
tients (Fig. S2, A–G). Thus, in both ELISA and multiplex 
particle-based flow cytometry, the only auto-Abs detected 
in the 33 patients with APS-I tested were directed against 
Table I. APS-I patients tested
Patients Gender Age Origin AIRE genotype Auto-Abs against Mucocutaneous candidiasis phenotype
 Luminex ELISA Age of onset Clinical features
IFN- IL-17A IL-17F IL-22 IL-17A IL-17F IL-22
APS-I 1 M 12 yr Saudi Arabia 845insc/845insc 8,584 7,406 1,874 11,810 0.11 0.21 2.41 18 mo Mouth, nails, esophagus
APS-I 2 M 9 yr Africa c958del/c958del 1,070 1,264 23,963 13,661 0.03 2.16 2.41 6 yr Nails, scalp, eyes
APS-I 3 M 13 yr Africa c958del/c958del 6,467 4,824 28,271 13,265 0.03 2.61 2.51 – Nails
APS-I 4 F 26 yr North Africa ex6_8del/ex6_8del 10,836 828 1,765 761 0.02 0.11 0.26 16 yr Nails, scalp
APS-I 5 M 25 yr North Africa ex6_8del/ex6_8del 12,785 1,448 16,980 2,758 0.04 1.33 0.26 7 yr Nails, scalp, digestive tract
APS-I 6 F 10 yr North Africa ex6_8del/ex6_8del 3,705 1,998 16,742 5,691 – 1 1.09 1 mo Mouth, eyes, vulva
APS-I 7 M 10 yr France R257X/P539L 20,109 27,523 25,409 18,446 2.29 1.95 2.83 2 mo Mouth, esophagus, respiratory tract
APS-I 8 F 21 yr Ireland 964del13/964del13 14,169 192 1,645 5,914 0.02 0.13 0.21 3 yr Mouth, scalp, skin
APS-I 9 M 20 yr Ireland 964del13/964del13 12,325 455 6,135 11,345 0.03 0.31 2.06 3 yr Mouth, nails, perineum
APS-I 10 F 29 yr UK 964del13/964del13 9,371 734 15,140 615 0 0.11 0.03 4 yr Mouth, esophagus, nails
APS-I 11 F 36 yr UK 964del13/964del13 12,078 148 4,439 102 0.01 0.15 0.16 Childhood Mouth, esophagus, vagina
APS-I 12 F 41 yr UK 964del13/964del13 6,098 17,201 24,837 9,749 0.16 0.47 0.64 4 yr Mouth, nails, vagina, anus
APS-I 13 F 18 yr Ireland 964del13/964del13 13,379 367 548 2,708 0.02 0.1 0.18 Childhood Skin, scalp
APS-I 14 M 12 yr Ireland 964del13/964del13 13,555 24,983 17,131 22,225 0.36 0.35 1.06 Few weeks Mouth, nails, scalp
APS-I 15 M 18 yr UK 964del13/964del13 16,906 28,484 25,907 20,585 2.34 0.5 1.07 3 yr Mouth, nails
APS-I 16 M 18 yr UK 964del13/964del13 15,473 28,262 23,926 12,034 1.89 0.52 0.3 3 yr Mouth, nails
APS-I 17 M 13 yr Ireland 964del13/964del13 8,086 805 23,917 14,558 0.02 0.64 0.91 5 yr Mouth, nails
APS-I 18 F 10 yr UK 964del13/964del13 13,053 5,282 27,409 15,236 0.03 1.52 0.61 Few weeks Mouth
APS-I 19 M 6 yr UK 964del13/964del13 13,797 13,588 28,025 13,575 0.25 1.84 1.83 Birth Mouth, perineum
APS-I 20 M 17 yr UK 964del13/964del13 11,946 11,272 25,904 2,129 0.08 0.39 0.12 7 yr Penis, perineum
APS-I 21 M 9 yr UK 964del13/964del13 13,127 752 12,048 18,039 0.08 0.44 1.11 2 yr Esophagus, nails
APS-I 22 F 52 yr UK 964del13/c.769C>T 8,012 955 22,886 4,502 ND ND ND Childhood Mouth
APS-I 23 M 16 mo Hungary R257X/R257X 23,216 20,035 4,531 21,012 0.55 0.08 2.31 – None
APS-I 24 M 18 yr Hungary R257X/C449fsX479 23,486 1,708 28,012 18,937 0.05 1.97 0.45 – None
APS-I 25 M 14 yr Hungary R257X/L323fsX373 23,923 2,025 9,169 5,259 0.06 0.15 0.18 – None
APS-I 26 F 21 yr Hungary R257X/R257X 23,120 12,359 28,834 11,583 0.43 2.86 0.16 – None
APS-I 27 M 28 yr Canada 964del13/964del13 21,225 737 7,576 5,047 0.02 0.09 0.04 3 yr Mucosa, skin, nails, eyes, scalp
APS-I 28 F 31 yr Canada 964del13/964del13 22,324 26,214 25,064 1,178 0.91 0.78 0.03 Birth Mucosa, skin, nails, eyes, scalp
APS-I 29 F 16 yr Canada delT253/R257X 24,099 2,268 13,563 15,899 0.08 0.79 0.14 2 yr Nails
APS-I 30 M 19 yr Canada delT253/R257X 21,442 153 448 1,264 0.03 0.04 0.24 3 yr Mucosa, skin, nails
APS-I 31 F 5 yr Canada 964del13/964del13 22,798 26,120 28,667 19,954 1.99     >3 1.83 6 mo Mucosa
APS-I 32 F 31 yr UK 964del13/964del13 14,718 2,155 27,222 14,358 ND ND ND 15 yr Mouth, nails
APS-I 33 F 7 yr UK 964del13/964del13 15,332 25,648 26,358 22,808 ND ND ND 4 yr Mouth, nails, scalp
Sex; age; country of origin; AIRE genotype; levels of auto-Abs against IFN-, IL-17A, IL-17F, and IL-22 measured by Luminex (FI values) or classical ELISA (OD values); and 
candidiasis phenotype are shown.
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tions of plasma samples from patients (up to 0.1%; not de-
picted) completely abolished fibroblastic cell responses to 
such high concentrations of rIL-17 (Fig. 3), whereas control 
plasma had no effect. Lower concentrations of IL-17A failed 
to induce IL-6, even in the presence of control plasma (un-
published data). The lack of robust bioassays precluded as-
sessments of the possible neutralizing effects of auto-Abs 
against IL-17F and IL-22. Thus, all patients with APS-I 
tested had high titers of auto-Abs against IL-17A, IL-17F, 
and IL-22 in their plasma, and these auto-Abs were specific 
and neutralizing, at least in the patients tested. These data 
suggest that most patients with APS-I carry neutralizing 
auto-Abs against IL-17A, IL-17F, and IL-22.
APS-I patients may display auto-Abs against IL-17 cyto-
kines as a result of impaired AIRE-dependent tolerance in-
duction if the expression of the corresponding cytokine genes 
is normally controlled by AIRE in the thymus or in second-
ary lymphoid organs. Whatever the mechanism, these data 
suggest that impaired IL-17 immunity may account for CMC 
in patients with APS-I. In particular, these data are consistent 
with the impaired IL-17 immunity reported in other patients 
with known inborn errors of immunity predisposing to 
CMC (and other infectious diseases). Indeed, patients with 
low proportions (IL12B, IL12RB1) or a lack of (STAT3) 
IL-17–producing circulating T cells suffer from mild (IL12B, 
IL12RB1) or severe (STAT3) CMC, respectively. Patients 
with APS-I and auto-Abs against IL-17 cytokines do not suf-
fer from severe staphylococcal disease, unlike STAT3-deficient 
patients (Freeman and Holland, 2009). Impaired IL-17 im-
munity probably contributes to staphylococcal disease in 
STAT3-deficient patients, as epithelial cells in the skin and 
biological assay. We incubated fibroblasts from a healthy 
control with up to 50 ng/ml rIL-17A in the presence of 
plasma from healthy individuals, or from a patient with APS-
I and auto-Abs against IL-17, as detected by ELISA and 
Western blotting. We then measured the induction of IL-6 
by ELISA on the supernatant. Strikingly, even strong dilu-
Figure 2. Specific auto-Abs against IL-17A, IL-17F, and/or IL-22 
in the plasma from patients with APS-I. Western blot against rIL-17A, 
rIL-17F, rIL-22, and rIL-23 were performed using plasma from a healthy 
individual or from five patients with APS-I, diluted 1:500. Representative 
data for three experiments are shown. Dashed lines indicate that inter-
vening lanes have been spliced out.
Figure 1. High titers of auto-Abs against IFN-, IL-17A, IL-17F, and IL-22 in the plasma from patients with APS-I. Anti–IFN-, –IL-17A, –IL-17F, 
and –IL-22 circulating IgG titers were measured by multiplex particle-based flow cytometry in 33 samples from patients with APS-I and in 37 samples from 
healthy controls. FI is plotted on the y axis. Representative data for two experiments are shown.
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coccal disease, as STAT3- and Tyk2-deficient patients suffer 
from staphylococcal disease and have a poor cellular response 
to IL-6 (Minegishi et al., 2006, 2007, 2009). However, no 
germline mutation in the gene encoding IL-6 or its receptor 
has yet been reported in similar patients. This description of 
patients with auto-Abs against IL-17 cytokines is the fourth 
reported example of pathogenic auto-Abs against human cyto-
kines. Other auto-Abs against cytokines not tested in this 
study, including some that would impair the development 
of IL-17–producing T cells, may also contribute to the de-
velopment of CMC in APS-I patients.
MATERIALS AND METHODS
Patients. 33 patients with APS-I (18 male and 15 female patients; Table I 
and Table S1), 103 patients with endocrine/autoimmune disorders, and 37 
healthy controls (15 male and 22 female subjects) were enrolled in this 
study, with informed consent and approval obtained by the Necker Hos-
pital and Medical School Institutional Review Board (IRB) and the 
Rockefeller University IRB.
Plasma and serum samples. Plasma and serum samples from the patients 
and controls were frozen at 20°C immediately after collection.
ELISA. ELISA was performed as previously described (Puel et al., 2008). In 
brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher Scientific) were coated 
by incubation overnight at 4°C with 2 µg/ml rIL-6, rIL-12p70, rIL-17A, rIL-
17F, rIL-21, rIL-22, rIL-23, rIL-26 monomer, rIL-26 dimer, rTGF-, and 
rIFN- (R&D Systems). Plates were then washed (PBS/Tween 0.005%), 
blocked by incubation with the same buffer supplemented with 5% nonfat 
milk powder, washed, and incubated with 1:500 dilutions of plasma samples 
from the patients or controls for 2 h at room temperature (or with specific 
mAbs as positive controls). Plates were thoroughly washed. Horseradish per-
oxidase (HRP)–conjugated Fc-specific IgG fractions from polyclonal goat an-
tiserum against human IgG or IgA (Nordic Immunological Laboratories) were 
added to a final concentration of 2 µg/ml. Plates were incubated for 1 h at 
room temperature and washed. Substrate was added and OD was measured.
Multiplex particle-based flow cytometry. Recombinant human cyto-
kines (rIL-1, rIL-6, rIL-10, rIL-12p40, rIL-12p70, rIL-17A, rIL-17F, 
rIL-18, rIL-22, rIL-23, rIL-26 monomer, rIL-26 dimer, rIFN-, rIFN-, 
rIFN-, rTNF, and rGM-CSF; R&D Systems) were covalently coupled to 
carboxylated beads (Bio-Plex; Bio-Rad Laboratories). Beads were first ac-
tivated with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochlo-
ride (Thermo Fisher Scientific) in the presence of N-hydroxysuccinimide 
(Thermo Fisher Scientific), according to the manufacturer’s instructions, to 
form amine-reactive intermediates. The activated beads were incubated 
with the corresponding cytokines at a concentration of 20 µg/ml in the re-
action mixture for 3 h at room temperature on a rotator. Beads were 
washed and stored in blocking buffer (10 mM PBS, 1% BSA, 0.05% NaN3). 
Cytokine-coupled beads were incubated with plasma or serum from pa-
tients for 1 h in 96-well filter plates (MultiScreenHTS; Millipore) at room 
temperature in the dark on a horizontal shaker. Fluids were aspirated with 
a vacuum manifold and beads were washed three times with 10 mM 
PBS/0.05% Tween 20. Beads were incubated for 30 min with a PE-labeled 
anti–human IgG-Fc antibody (Leinco/Biotrend), washed as described, and 
resuspended in 100 µl PBS/Tween. They were then analyzed on an ana-
lyzer (Bio-Plex) using Bio-Plex Manager 3.0 software (both from Bio-Rad 
Laboratories). Successful coupling of the cytokines to their respective bead 
sets was verified with specific mAbs.
Western blotting. We subjected 500 ng rIL-17A, rIL-17, rIL-22, rIL-23 
(R&D Systems), or BSA to SDS-PAGE (10% acrylamide) under reducing 
conditions. The protein bands were electroblotted onto nitrocellulose mem-
branes (iBlot Gel Transfer Stacks; Invitrogen). Membranes were blocked by 
lungs, the organs most frequently affected by staphylococcal 
infection in these patients, specifically rely on IL-17 stimula-
tion for the induction of known antistaphylococcal target 
genes (Minegishi et al., 2009). The lack of overt staphylo-
coccal disease in most APS-I patients may result from residual 
IL-17 immunity, as observed to an even greater extent in pa-
tients with IL-12p40 and IL-12R1 deficiencies who also 
control staphylococcal infections normally (Filipe-Santos 
et al., 2006). In any case, proof that human IL-17 cytokines 
play an essential role in immunity to Candida will require the 
identification of mutations specifically impairing IL-17 im-
munity in other patients with inherited, isolated CMC with-
out APS-I (Ryan et al., 2008; Hong et al., 2009). The recent 
observation that some patients with isolated CMC have 
smaller than normal proportions of IL-17–producing T cells 
and produce low levels of IL-17 suggests that this may be 
plausible (unpublished data; Eyerich et al., 2008).
Various human diseases seem to be caused by the pro-
duction of auto-Abs against cytokines. Patients with pulmo-
nary alveolar proteinosis were shown to display auto-Abs 
against GM-CSF in 1999 (Kitamura et al., 1999). Mutations 
in the GM-CSF receptor were subsequently found in other 
patients, establishing a causal relationship between impaired 
GM-CSF immunity and alveolar proteinosis (Martinez-
Moczygemba et al., 2008; Suzuki et al., 2008). Patients with 
mycobacterial diseases and inherited IFN-R1 deficiency 
were first reported in 1996 (Filipe-Santos et al., 2006). Auto-
immune phenocopies, with auto-Abs against IFN-, were 
subsequently found in other patients (Döffinger et al., 2004; 
Kampmann et al., 2005; Patel et al., 2005). We recently re-
ported a patient with auto-Abs against IL-6 and staphylo-
coccal disease (Puel et al., 2008). There may be a causal 
relationship between auto-Abs against IL-6 and staphylo-
Figure 3. Neutralizing auto-Abs against IL-17A in the plasma 
from a patient with APS-I. IL-6 production, after 48 h of stimulation 
with 50 ng/ml IL-17A, by control SV-40–transformed fibroblasts incu-
bated with 10% plasma from two controls or from one patient (APS-I 
patient 7; means and errors bars from duplicates are shown). The data 
shown are representative of two experiments.
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incubation for 1 h at room temperature with PBS supplemented with 5% 
BSA and 0.05% Tween 20, and were washed and incubated overnight at 
4°C with plasma samples from a patient or a control diluted 1:500 in PBS, 
5% BSA, 0.01% Tween 20. The membranes were washed three times and 
incubated for 1 h at room temperature with HRP-coupled anti–human IgG 
and used at a final concentration of 0.67 µg/ml. The membranes were 
washed three times and developed for ECL (GE Healthcare).
Neutralization assay. SV-40–transformed control fibroblasts were plated 
in 24-well plates (60,000 fibroblasts/well) in 0.5 ml DMEM/10% FCS (In-
vitrogen). On the following day, cells were washed in 1× PBS (Invitrogen) 
and incubated with 10% plasma (from a control or a patient) in DMEM. 
They were left unstimulated or were stimulated with 50 ng/ml rIL-17A 
(R&D Systems). The supernatants were collected 24 and 48 h after stimula-
tion, and IL-6 production was assessed by ELISA (Sanquin Mast Diagnostic) 
according to the manufacturer’s instructions.
Online supplemental material. Fig. S1 shows anti–IL-17A, –IL-17F, and 
–IL-22 IgG auto-Abs measured by ELISA in plasma from APS-I patients and 
controls. Fig. S2 shows anti–TGF-1, –IL-6, –IL-21, –IL-23, –IL-12, –IFN-, 
and –IL-26 IgG auto-Abs measured by ELISA in plasma from controls 
and APS-I patients. Fig. S3 shows anti–IL-1, –IL-6, –IL-23, –IL-26, –IL-
12, –IFN-, –GM-CSF, –IFN-, –IL-10, –IL-18, and -TNF IgG auto-Abs 
measured by multiplex particle-based flow cytometry in plasma from healthy 
controls and APS-I patients. Fig. S4 shows anti–IFN-, –IL-17A, –IL-17F, 
and –IL-22 IgG auto-Abs in 100 patients suffering from autoimmune and/or 
endocrine disorders. Table S1 shows the autoimmune/endocrine phenotypes 
and treatments of each APS-I patient tested. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20091983/DC1.
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 Figure S1.  High titers of auto-Abs against IL-17A, IL-17F, and IL-22 in the plasma from patients with APS-I. Anti–IL-17A, –IL-17F, and –IL-
22 circulating IgG titers were measured by classical ELISA on 30 samples from patients with APS-I and 37 samples from healthy controls. OD 450–630 is 
plotted on the y axis. The data shown are representative of two experiments. 
 Figure S2.  No auto-Abs against TGF-  1, IL-6, IL-21, IL-23, IL-12, IFN-  , and IL-26 in the plasma from patients with APS-I. (A–G) Anti–
TGF-  1, –IL-6, –IL-21, –IL-23, –IL-12, –IFN-  , and –IL-26 circulating IgG titers were measured by classical ELISA in 37 samples from healthy controls and 
30 samples from patients with APS-I. OD 450–630 is plotted on the y axis. 
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 Figure S3.  No auto-Abs against IL-1  , IL-6, IL-23, IL-26, IL-12, IFN-  , GM-CSF, IFN-  , IL-10, IL-18, and TNF in the plasma from pa-
tients with APS-I. (A–K) Anti–IL-1  , –IL-6, –IL-23, –IL-26, –IL-12, –IFN-  , –GM-CSF, –IFN-  , –IL-10, –IL-18, and -TNF circulating IgG titers measured by 
multiplex particle-based fl ow cytometry in 37 samples from healthy controls and 33 samples from patients with APS-I. FI is plotted on the y axis. 
 Figure S4.  No auto-Abs against IL-17A, IL-17F, and IL-22 in the plasma from patients with autoimmune and/or endocrine disorders. (A and 
B) Anti–IFN-  , –IL-17A, –IL-17F, and –IL-22 antibodies were measured in 103 patients suffering from autoimmune and/or endocrine disorders: rheumatoid 
arthritis ( n = 12), lupus ( n = 17), Sjögren’s syndrome ( n = 8), pernicious anemia/autoimmune gastritis ( n = 4), autoimmune vasculitis ( n = 10), autoimmune 
skin diseases ( n = 4), phospholipid syndrome ( n = 5), autoimmune liver disease ( n = 3), celiac disease ( n = 2), CREST syndrome ( n = 7), autoimmune endo-
crine diseases (hypothyroidism,  n = 14; Graves’ disease,  n = 6; type 1 diabetes,  n = 6), miscellaneous diseases ( n = 2), and thymoma ( n = 3). 
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 Table S1. APS-I patients tested 
Patients Endocrine/autoimmune phenotype Treatment
APS-1 Kidneys Fluconazole, voriconazole
APS-2 Adrenal and parathyroid glands, pancreas, liver, celiac 
disease
Terbinafi ne, teriparatide, uvedose, hydrocortisone, carbamazepine
APS-3 Adrenal and parathyroid glands Terbinafi ne, teriparatide, uvedose, hydrocortisone
APS-4 Parathyroid, thyroid, adrenal, and ovarian glands, 
pancreas, Biermer disease
Levothyrox, rocaltrol, hydrocortisone, fl udrocortisone, Creon
APS-5 Adrenal, parathyroid, and hypophyse glands, 
pancreas, Biermer disease
Fluconazole, HydroC, FludroC, Creon, Rocaltrol, Caltrate, Magne B6, uvedose, 
tardiferon, Androtardyl, genotonorm
APS-6 None Fluconazole, Un-  , cyclosporine eye drops
APS-7 Adrenal glands Fluconazole, Ig, hydrocortisone, fl udrocortisone
APS-8 Parathyroid and adrenal glands Antifungals
APS-9 Parathyroid and adrenal glands, digestive tract Methotrexate, hydrocortisone, fl uconazole/itraconazole, antibiotics
APS-10 Parathyroid and adrenal glands, gonads, IDDM Adalat, spirolactone, 1-  , frusemide, vitamin B, hydrocortisone, 
fl uconazole/itraconazole, antibiotics
APS-11 Parathyroid and adrenal glands, gonads, 
IDDM, pernicious anemia
Vitamin B12, blood transfer for pernicious anemia, fl uconazole
APS-12 Parathyroid and adrenal glands, gonads, digestive tract Fluconazole/itraconazole
APS-13 Parathyroid and adrenal glands, gonads, 
digestive tract, enamel dysplasia
Calcitriol, vitamin D, prednisolone, Florinef, Fe, hormone replacement
APS-14 Adrenal glands, liver Fluconazole
APS-15 None Fluconazole
APS-16 Parathyroid and adrenal glands, digestive tract, enamel 
dysplasia
Hydrocortisone/fl udrocortisone, fl uconazole
APS-17 Adrenal glands, enamel dysplasia Hydrocortisone
APS-18 Parathyroid and adrenal glands, enamel dysplasia Fluconazole/itraconazole
APS-19 Adrenal glands, digestive tract Fluconazole/itraconazole, antibiotics, subcut Ig
APS-20 Parathyroid and adrenal glands Hydrocortisone,   calcidol, fl uconazole/itraconazole
APS-21 IDDM, liver, pancreas, digestive tract Fluconazole
APS-22 Parathyroid and adrenal glands, myopathy Fluconazole
APS-23 None None
APS-24 Parathyroid gland Rocaltron
APS-25 Parathyroid gland Rocaltron, Cortef, Astonin H
APS-26 Parathyroid and adrenal glands Rocaltron, Cortef, Genotropin, estrophen
APS-27 Parathyroid gland, enamel defect, Addison’s disease Hydrocortisone, fl udrocortisone, vitamin D 1,25 dihydroxycholecalciferol, Ca 
supp.
APS-28 Parathyroid and thyroid glands, 
Addison’s disease, enamel defect
Hydrocortisone, fl udrocortisone, levothyroxine, vitamin D 1,25 
dihydroxycholecalciferol, 
Ca supp., fl uconazole, amlodipine, perindopril, vitamin B12, Ca 2+ 
APS-29 Parathyroid gland, Addison’s disease Hydricotisone, fl udrocortisone, estrogen + progesterone (Demulen), 
vitamin D 1,25 dihydroxycholecalciferol, Ca carbonate
APS-30 Gonads Hydrocortisone, fl udrocortisone, 
vitamin D 1,25 dihydroxycholecalciferol, Ca 2+ carbonate
APS-31 Parathyroid gland, digestive tract Fludrocortisone, hydrocortisone, mycophenolate mofetil, pilocarpine, 
vitamin D 1,25 dihydroxycholecalciferol, Ca supp.
APS-32 Parathyroid gland, type 1 diabetes, 
Addison’s disease, lymphocytic leukemia
Fluconazole, vitamin B12, insulin, hydrocortisone, methotrexate
APS-33 Thyroid gland, auto-Abs to ovaries and adrenal glands Itroconazole
APS-I patients tested, with their respective autoimmune/endocrine phenotypes and treatments. IDDM, insulin-dependent diabetes mellitus.
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